<DOC>
	<DOCNO>NCT00430027</DOCNO>
	<brief_summary>The primary objective pilot study determine whether neoadjuvant capecitabine/oxaliplatin/cetuximab external beam radiation therapy follow surgical resection [ follow post operative adjuvant capecitabine , oxaliplatin cetuximab ] feasible tolerable .</brief_summary>
	<brief_title>Preoperative Capecitabine , Oxaliplatin , Cetuximab , Radiation Therapy Locally Advanced Esophageal Adenocarcinoma</brief_title>
	<detailed_description>It clear new approach need improve therapeutic ratio esophageal cancer . This study propose evaluate novel combination preoperative capecitabine , oxaliplatin , cetuximab concurrently radiation therapy . This follow esophagectomy 6-9 week completion chemoradiation . Followed adjuvant chemotherapy . It hypothesize novel combination neoadjuvant capecitabine , oxaliplatin , cetuximab combine thoracoabdominal radiation therapy feasible result acceptable toxicity .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>sign informed consent patient 18 year age old biopsy proven , nonrecurrent primary adenocarcinoma thoracic esophagus gastroesophageal junction , disease confine esophagus periesophageal soft tissue , tumor gastroesophageal junction must limit great 2 cm gastric cardia clinical stage T3 , N01 T12 , N1 M0 M1a ( celiac axis lymph node allow ) Karnofsky Performance Status &gt; 60 % forced expiratory volume one second ( FeV1 ) must &gt; 1.0 L adequate bone marrow reserve equal absolute neutrophil count ( ANC ) &gt; 1500/mcl , total white blood cell count ( WBC ) &gt; 3000/mcl , platelet &gt; 100,000/mcl hemoglobin &gt; 10.0 g/dl ( transfusion permit ) adequate hepatic function direct serum bilirubin &lt; 2 time upper limit normal , total bilirubin &lt; 1.5 time upper limit normal , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) &lt; 2.5 time upper limit normal , Alkaline phosphatase &lt; 2.5 time upper limit normal creatinine clearance &gt; 50 ml/min female patient childbearing potential must negative serum urin pregnancy test within 7 day prior start therapy previous resection attempt resection esophageal cancer woman pregnant lactate life expectancy &lt; 3 month serious , uncontrolled concurrent infection ( ) prior fluoropyrimidine therapy prior unanticipated severe reaction fluoropyrimidine therapy , know hypersensitivity 5fluorouracil know Dihydro Pyrimidine Dehydrogenase Deficiency ( DPD ) deficiency treatment carcinoma within 5 year , except cure nonmelanoma skin treat insitu cervical cancer history evidence uncontrolled diabetes surgical procedure within 6 month study entry participation investigational drug study within 4 week precede start study treatment prior therapy andy agent specifically target Epidermal Growth Factor Receptor ( EGFR ) pathway prior severe infusion reaction monoclonal antibody acute hepatitis know HIV clinically significant cardia disease evidence metastases serious uncontrolled medical condition investigator feel might compromise study participation major surgery within 4 week start treatment without complete recovery lack physical integrity upper gastrointestinal tract malabsorption syndrome know , exist uncontrolled coagulopathy unwillingness give write informed consent unwillingness participate inability comply protocol duration study neuropathy grade 2 great</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Esophageal</keyword>
	<keyword>Esophagus</keyword>
</DOC>